1.Methods VEGF and bFGF as angiogenic factors, thalidomide asan angiogenesis inhibitor, various properties of vascular endothelialcells (RF/6A and SVEC) were detected in vitro with MTT assay,wound migration assay, invasion assay and tube formation assay.
方法以VEGF,bFGF为血管新生因子,以Thalidomide血管新生抑制因子对体外培养的血管内皮细胞系(RF/6A,SVEC)应用MTT试验,迁移试验,浸润试验和管状形成试验检测内皮细胞的各种特性;
2.Objective To explore the effects of proteasome inhibitor PS-341、 As_2O_3、Dexamethasone(Dex) and Thalidomide(Thal) on the abnormal expressions of cytokines of mesenchymal stem cells(MSCs) in patients with multiple myeloma (MM) .
目的 研究蛋白酶体抑制剂PS-341(Velcade)、三氧化二砷(As_2O_3)、地塞米松(Dexamethasone，Dex)和沙利度胺(Thalidomide，Thal)对多发性骨髓瘤(Multiple Myeloma，MM)骨髓间充质干细胞(Mesenchymal Stem Cells，MSCs)IL-6、IL-1β、SCF异常表达的影响。
3.Lenalidomide is a noel immune modulating, non-chemotherapy, cancer drug that is chemically similar to thalidomide, but is more potent in the laboratory and appears to lack some of the more common side effects of thalidomide.
来那度胺是一种新型的免疫调节剂用来治疗肿瘤，它是非化疗药物，化学结构与反应停相似，但是在实验室研究效果更好，副作用更少。
4.One group received Thalidomide+MP, Thalidomide 25mg/d,p. o. , d1～21.MP(Mel.10mg/?·d,p.o.,four days,Prep.2mg/kg·d,p.o.,four days ,for four weeks).
方法采用配对研究方法观察沙利度胺治疗多发性骨髓瘤19例的治疗效果,一组采用沙利度胺+MP,使用剂量:沙利度胺25mg/d口服d1～21+MP方案(马法兰10mg/?·d,口服共4天,泼尼松2mg/kg·d,口服共4天,共4周。)
5.Thalidomide (200 mg/kg),paclitaxel (13 mg/kg),or Thalidomide (200 mg/kg) plus paclitaxel (13 mg/kg),which were dissolved in 0.5% CMC suspension,was peritoneally injected respectively for each group from the second day of building model. The mice with 0.5% CMC alone served as control group.
各组模型自建立次日起分别经腹腔注射0.5%羧甲基纤维素钠(CMC)、反应停(200mg/kg体重)、紫杉醇(13mg/kg体重)、反应停(200mg/kg体重)+紫杉醇(13mg/d)。
6.Objective To obserye the effects of Thalidomide andLD-Arac therapy in High Risk Myelodysplastic Syndromeombination(MDS)); Methods 27 MDS patients were treated by Thalidomide and LD-Arac.
目的观察沙利度胺及小剂量阿糖胞苷(LD-Arac)治疗高危骨髓增生异常综合征的疗效,研究高危MDS的治疗方法。
7.Methods 29 patients with MM received the treatment of thalidomide with VAD. The initial dose of thalidomide was 200mg/d, then does increased 100mg/d to 400-600mg/d every week until the maximal tolerance.
方法29例MM患者接受沙利度胺联合VAD治疗方案:沙利度胺自VAD方案开始持续给药,一日200mg,以后每周递增100mg,直至一日400～600mg;
8.Conclusion The results show that LD-Arac and Thalidomide therapy, no serious bone marrow refrain and no infection and bleeding,is an effective method in improveing the patient prognosis.
结论LD-Arac和沙利度胺治疗高危MDS确有明显疗效,无严重骨髓抑制,无感染及出血,明显改善高危MDS病人的预后。
9.deformed thalidomide babies; his poor distorted limbs; an ill-shapen vase; a limp caused by a malformed foot; misshapen old fingers.
畸形的镇定剂婴儿；他四肢畸形；难看的花瓶；因足部畸形而一跛一跛地走；苍老变形的手指。
10.Arac10～15mg/m2 were given by hypodermic injection every12 hours for15～21days and repeated after 10～15 days,Thalidomide were given by po 100mg·d-1,and twice a day.
方法对27例高危骨髓增生异常综合征患者,应用LD-Arac10～15mg/m2,每12h1次皮下注射,15～21天1疗程,间隔10～15天重复。
